These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 6658101)

  • 1. [Policy for the prevention of meningococcal infections in Belgium].
    De Wals P
    Rev Epidemiol Sante Publique; 1983; 31(3):273-82. PubMed ID: 6658101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meningococcal B vaccine: new drug. The only vaccine against some serogroup B meningococci.
    Prescrire Int; 2008 Jun; 17(95):95-7. PubMed ID: 18623907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased case-fatality rate associated with outbreaks of Neisseria meningitidis infection, compared with sporadic meningococcal disease, in the United States, 1994-2002.
    Brooks R; Woods CW; Benjamin DK; Rosenstein NE
    Clin Infect Dis; 2006 Jul; 43(1):49-54. PubMed ID: 16758417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meningococcal C vaccines: the Canadian experience.
    De Wals P
    Pediatr Infect Dis J; 2004 Dec; 23(12 Suppl):S280-4. PubMed ID: 15597070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A retrospective survey of clusters of meningococcal disease in England and Wales, 1993 to 1995: estimated risks of further cases in household and educational settings.
    Hastings L; Stuart J; Andrews N; Begg N
    Commun Dis Rep CDR Rev; 1997 Dec; 7(13):R195-200. PubMed ID: 9447784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Control of a school outbreak of serogroup B meningococcal disease by chemoprophylaxis with azithromycin and ciprofloxacin].
    González de Aledo Linos A; García Merino J
    An Esp Pediatr; 2000 Nov; 53(5):412-7. PubMed ID: 11521657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidemiologic characteristics of an outbreak of serogroup C meningococcal disease and the public health response.
    Houck P; Patnode M; Atwood R; Powell K
    Public Health Rep; 1995; 110(3):343-9. PubMed ID: 7610228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prevention of secondary cases of invasive meningococcal infection: role of chemoprophylaxis and vaccination].
    Chuard C; Regamey C
    Rev Med Suisse Romande; 2003 Mar; 123(3):151-4. PubMed ID: 15095699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of meningococcal serogroup C conjugate vaccine in Scotland.
    Mooney JD; Christie P; Robertson C; Clarke SC
    Clin Infect Dis; 2004 Aug; 39(3):349-56. PubMed ID: 15307001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of different policies in preventing meningococcal disease clusters following a single case in day-care and pre-school settings in Europe.
    Boccia D; Andrews N; Samuelsson S; Heuberger S; Perrocheau A; Stuart JM; European Monitoring Group on Meningococci
    Epidemiol Infect; 2006 Aug; 134(4):872-7. PubMed ID: 16420726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meningococcal disease and prevention at the Hajj.
    Borrow R
    Travel Med Infect Dis; 2009 Jul; 7(4):219-25. PubMed ID: 19717104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in the evolution of meningococcal disease, 2001-2008, Catalonia (Spain).
    Martínez AI; Dominguez A; Oviedo M; Minguell S; Jansa JM; Codina G; Vazquez JA;
    Vaccine; 2009 May; 27(25-26):3496-8. PubMed ID: 19200816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Meningococcal disease in Spain, 1990-1997. Change in its epidemiological pattern].
    de Mateo Ontañón S
    Rev Esp Salud Publica; 2000; 74(4):387-96. PubMed ID: 11031848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meningococcal disease in catalonia 1 year after mass vaccination campaign with meningococcal group C polysaccharide vaccine.
    Cardeñosa N; Domínguez A; Martínez A; Alvarez J; Pañella H; Godoy P; Minguell S; Camps N; Vázquez JA;
    Infection; 2003 Dec; 31(6):392-7. PubMed ID: 14735381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccinating adolescents against meningococcal disease in Canada: a cost-effectiveness analysis.
    De Wals P; Coudeville L; Trottier P; Chevat C; Erickson LJ; Nguyen VH
    Vaccine; 2007 Jul; 25(29):5433-40. PubMed ID: 17560695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meningococcal disease in California. Epidemiology and management.
    Juels C; Morrison FR; Overturf GD; Roberto RR; Chin JC
    West J Med; 1978 Mar; 128(3):195-202. PubMed ID: 636408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of serogroup C meningococcal polysaccharide vaccine: results from a case-control study in Quebec.
    De Wals P; Deceuninck G; De Serres G; Boivin JF; Duval B; Remis R; Massé R
    Clin Infect Dis; 2005 Apr; 40(8):1116-22. PubMed ID: 15791510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meningococcal disease epidemiology and control in New Zealand.
    Wilson N; Baker M; Martin D; Lennon D; O'Hallahan J; Jones N; Wenger J; Mansoor O; Thomas M; Jefferies C
    N Z Med J; 1995 Oct; 108(1010):437-42. PubMed ID: 7478351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating the post-licensure effectiveness of a group B meningococcal vaccine in New Zealand: a multi-faceted strategy.
    Ameratunga S; Macmillan A; Stewart J; Scott D; Mulholland K; Crengle S;
    Vaccine; 2005 Mar; 23(17-18):2231-4. PubMed ID: 15755602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The concept of "tailor-made", protein-based, outer membrane vesicle vaccines against meningococcal disease.
    Holst J; Feiring B; Naess LM; Norheim G; Kristiansen P; Høiby EA; Bryn K; Oster P; Costantino P; Taha MK; Alonso JM; Caugant DA; Wedege E; Aaberge IS; Rappuoli R; Rosenqvist E
    Vaccine; 2005 Mar; 23(17-18):2202-5. PubMed ID: 15755595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.